Cerenome, Inc.
CNSYCerenome, Inc. in brief
Cerenome, Inc. is a listed company in the Biotechnology industry, based in the USA. It was founded in 1996. Its market value was $17 M on 30 October 2026, which makes it the 24,718th largest listed company in the world and the 4,184th largest in the USA on this site. In the year to December 2025 it had sales of $5 M and a net loss of $22 M. It employs about 28 people. Its shares trade under the symbol CNSY (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Cerenome, Inc.
Plus Therapeutics is a U.S. healthcare company developing and commercializing precision diagnostics and targeted radiopharmaceuticals for central nervous system cancers. CNSide Diagnostics, LLC is our wholly owned subsidiary that develops and commercializes proprietary laboratory-developed tests, such as CNSide®, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. In radiopharmaceuticals, our lead candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery and intraventricular brain (Ommaya reservoir) catheters. Our acquired radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere is designed to treat many solid organ cancers including primary and secondary liver cancers by intra-arterial injection.
Cerenome, Inc. timeline
- 1996
- 🏁· approximateFounded
- 2000
- 🔔· approximateInitial public offering on Nasdaq as PSTV
- 2001
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2005
- ✎Renamed Cytori Therapeutics, Inc.Formerly Macropore Inc.
- 2019
- ✎Renamed Plus Therapeutics, Inc.Formerly Cytori Therapeutics, Inc..
- 2024
- 💰Record revenue of $6 millionFY2024, the highest of the 4 years on record.
- 2026
- ✎Renamed Cerenome, Inc.Formerly Plus Therapeutics, Inc..
Events of Cerenome, Inc. from Wikidata, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,695 (Jan 2020) · #4,580 (Jan 2021) · #5,441 (Jan 2022) · #5,580 (Dec 2022) · #5,533 (Jul 2023) · #4,557 (Jan 2024) · #2,189 (Mar 2026) · #4,137 (Oct 2026) · #4,186 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 4.0×
- Price / book
- 4.3×
- Free cash flow yield
- -122.6%
- Net margin (TTM)
- -621.4%
- Operating margin
- -293.7%
- Return on equity
- -652.5%
- Liabilities / assets
- 75.6%
- Net debt
- $-14M
- Revenue growth
- -10.5%
- R&D / revenue
- 160.8%
- Revenue per employee
- $186 K
- Profit per employee
- $-800 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $5M | -10.5% | $-15M | $-22M | -429.8% |
| Dec 2024 | $6M | +18.5% | $-15M | $-13M | -223.0% |
| Dec 2023 | $5M | — | $-13M | $-13M | -271.3% |
| Dec 2022 | — | — | $-20M | $-20M | — |
| Dec 2021 | — | — | $-12M | $-13M | — |
| Dec 2020 | — | — | $-10M | $-8M | — |
| Dec 2019 | — | — | $-4M | $-11M | — |
| Dec 2018 | $4M | — | $-9M | $-13M | -344.1% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-21M | $0M | $-21M | $-0.29 | — |
| Dec 2024 | $-11M | $0M | $-11M | $-2.34 | — |
| Dec 2023 | $-13M | $0M | $-13M | $-4.24 | — |
| Dec 2022 | $-13M | — | — | $-11.58 | — |
| Dec 2021 | $-10M | — | — | $-1.11 | — |
| Dec 2020 | $-8M | — | — | $-1.86 | — |
| Dec 2019 | $-6M | $0M | $-6M | $-8.27 | — |
| Dec 2018 | $-12M | $0M | $-12M | $-86.98 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $1M (-48.6% on a year earlier), net income $-9M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Nov 12, 20268-KCurrent reportDirectors or officers changed · Other events
- Oct 2, 20268-KCurrent reportOther events
- Sep 10, 20268-KCurrent reportMaterial agreement · New financial obligation · Unregistered share sale · Other events
- Aug 14, 202610-QQuarterly report · period to Jun 2026
- Aug 14, 20268-KCurrent reportResults of operations
- Aug 4, 20268-KCurrent reportBylaws amended
- Jun 5, 20268-KCurrent reportMaterial agreement
- May 15, 20268-KCurrent reportShareholder vote
- May 15, 202610-QQuarterly report · period to Mar 2026
- May 15, 20268-KCurrent reportResults of operations
- Apr 21, 20268-KCurrent reportOther events
- Apr 9, 20268-KCurrent reportDirectors or officers changed
Official filings of Cerenome, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $5 M
- Operating income
- $-15 M
- Net income
- $-22 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $16 M
- Total liabilities
- $12 M
- Total equity
- $4 M
As of December-2025
Top 22 institutional investors in Cerenome, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 304,745 | 0 (0.00%) | 4.02% | $1 M | Nov 13, 2026 |
| 2 | BlackRock, Inc. | 99,559 | +3,576 (+3.73%) | 1.31% | $0 M | Nov 13, 2026 |
| 3 | Geode Capital Management, LLC | 81,743 | +5,588 (+7.34%) | 1.08% | $0 M | Nov 6, 2026 |
| 4 | Vanguard Fiduciary Trust Co | 36,868 | 0 (0.00%) | 0.49% | $0 M | Nov 13, 2026 |
| 5 | Ashton Thomas Private Wealth, LLC | 34,306 | 0 (0.00%) | 0.45% | $0 M | Nov 3, 2026 |
| 6 | State Street Corp | 30,853 | 0 (0.00%) | 0.41% | $0 M | Nov 12, 2026 |
| 7 | Northern Trust Corp | 14,612 | -904 (-5.83%) | 0.19% | $0 M | Nov 16, 2026 |
| 8 | XTX Topco Ltd | 11,547 | New | 0.15% | $0 M | Nov 16, 2026 |
| 9 | UBS Group AG | 3,118 | +2,648 (+563.40%) | 0.04% | $0 M | Nov 10, 2026 |
| 10 | Nuveen, LLC | 2,285 | New | 0.03% | $0 M | Nov 10, 2026 |
| 11 | Vanguard Global Advisers, LLC | 2,282 | 0 (0.00%) | 0.03% | $0 M | Nov 13, 2026 |
| 12 | Osaic Holdings, Inc. | 2,000 | 0 (0.00%) | 0.03% | $0 M | Nov 12, 2026 |
| 13 | Tower Research Capital LLC (TRC) | 1,844 | -111 (-5.68%) | 0.02% | $0 M | Nov 16, 2026 |
| 14 | Jpmorgan Chase & Co | 385 | New | 0.01% | $0 M | Nov 12, 2026 |
| 15 | Royal Bank Of Canada | 352 | New | 0.00% | $0 M | Nov 16, 2026 |
| 16 | SBI Securities Co., Ltd. | 251 | 0 (0.00%) | 0.00% | $0 M | Oct 22, 2026 |
| 17 | Morgan Stanley | 185 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 18 | Robinhood Markets, Inc. | 142 | — | 0.00% | $0 M | Nov 18, 2026 |
| 19 | Barclays PLC | 72 | -24 (-25.00%) | 0.00% | $0 M | Nov 6, 2026 |
| 20 | Wells Fargo & Company/mn | 6 | -6,150 (-99.90%) | 0.00% | $0 M | Nov 16, 2026 |
| 21 | Caitong International Asset Management Co., Ltd | 5 | -7 (-58.33%) | 0.00% | $0 M | Oct 29, 2026 |
| 22 | Global Retirement Partners, LLC | 4 | 0 (0.00%) | 0.00% | $0 M | Nov 10, 2026 |
Mutual funds holding Cerenome, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 203,500 | $1 M | 2.7% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 86,245 | $0 M | 1.1% | <0.01% | −96% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 39,144 | $0 M | 0.52% | <0.01% | −95% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 23,411 | $0 M | 0.31% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 10,332 | $0 M | 0.14% | <0.01% | −95% | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 9,966 | $0 M | 0.13% | <0.01% | −96% | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 2,849 | $0 M | 0.04% | <0.01% | −96% | May 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 1,518 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 135 | $0 M | <0.01% | <0.01% | −94% | Jun 30, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 20 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 10 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Cerenome, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Marc H. HedrickChief Executive Officer, Director | Option exercise | +6,387 | — | — | 50,870 | Form 4 |
| filed | Richard J. HawkinsDirector | Option exercise | +921 | — | — | 2,450 | Form 4 |
| filed | An Van Es-JohanssonDirector | Option exercise | +921 | — | — | 1,843 | Form 4 |
| filed | Howard ClowesDirector | Option exercise | +921 | — | — | 2,902 | Form 4 |
| filed | Ronald Asbury AndrewsDirector | Option exercise | +921 | — | — | 1,843 | Form 4 |
| filed | Sims Andrew John Hugh MacIntyreChief Financial Officer | Option exercise | +1,533 | — | — | 11,474 | Form 4 |
| filed | Kyle GuseDirector | Option exercise | +921 | — | — | 1,843 | Form 4 |
| filed | Marc H. HedrickChief Executive Officer, Director | Option exercise | +8,066 | — | — | 58,936 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Cerenome, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-25 reverse split ; 1-for-25 reverse split ; 1-for-16.67 reverse split ; 1-for-50 reverse split ; 1-for-10 reverse split ; 15-for-1 split
Trading halts
- 2026-11-03 15:58 UTC, code LUDP, resumed 16:03 UTC
- 2026-11-03 15:50 UTC, code LUDP, resumed 15:55 UTC
- 2026-11-03 15:43 UTC, code LUDP, resumed 15:48 UTC
- 2026-11-03 15:24 UTC, code LUDP, resumed 15:38 UTC
- 2026-04-01 23:50 UTC, code T3, resumed 13:00 UTC
Fails to deliver
- : 308 shares at $1.74
- : 28 shares at $1.76
- : 183 shares at $1.66
- : 4,117 shares at $1.64
- : 1,955 shares at $1.75
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Cerenome, Inc. scorecard#
Passes 2 of the 14 checks that could be worked out: strongest in financial health (1 of 3), weakest in growth (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation1 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median4.2×Price to book 4.2× against Biotechnology's median of 2.9×.
- ✓Price to sales below its peers' median4.0×Price to sales 4.0× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-122.6%Free cash flow is -122.6% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 3
- ✗Revenue grew in the newest year-10.5%Revenue down 10.5% in fiscal 2025.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-0.29 vs -2.34Diluted EPS -0.29 in fiscal 2025 against -2.34 the year before (report's currency).
- ✗Net income higher than five years earlier-$22 M-$22 M in fiscal 2025 against -$8 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$22 MNet income -$22 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-293.7%-293.7% against Biotechnology's median of -60.5% (243 companies).
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities1.2×Current ratio 1.23 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-45.99Z-score -45.99 (distress zone) for fiscal 2025.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Cerenome, Inc.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -293.7% | -60.5% | |
| Net margin | -429.8% | -68.9% | |
| Revenue growth | -10.5% | 15.8% | |
| Free cash flow margin | -400.2% | -61.5% |
4of 7on the Piotroski tests of financial strength
- Revenue fell 10.5% against the year before.
- Net loss of $22 million, the 17th loss-making year in a row.
- Free cash flow was negative: -$21 million.
Cerenome, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 5.2−10.5%100% | 5.8+18.5%100% | 4.9—100% | — | — | — | — | 3.7+36.5%100% | 2.7−42.2%100% | 4.7—100% | |
| Cost of revenue | — | — | — | — | — | — | — | 1.1−12.9%31.3% | 1.3−51.5%49.0% | 2.7—58.3% | |
| Gross profit | — | — | — | — | — | — | — | — | 0.1−92.5%5.4% | 1.9—41.7% | |
| Research and development | 8.4−20.8%161% | 11+9.2%182% | 9.7−0.1%197% | 9.7+82.2%— | 5.3+97.1%— | 2.7−49.7%— | 5.4−2.9%— | 5.5r8.6−52.7%150% | 12−27.9%434% | 16—348% | |
| Selling and marketing | — | — | — | — | — | — | 0.5−27.2%— | 0.6r2.0−82.1%17.5% | 3.6−0.5%134% | 3.6—77.6% | |
| General and administrative | 12+22.1%233% | 9.9+16.3%171% | 8.5−16.5%174% | 10+49.4%— | 6.9+7.0%— | 6.4+21.1%— | 5.3r4.8−5.2%— | 5.6r6.3−26.5%152% | 7.6−11.3%282% | 8.6—184% | |
| Operating expenses | 21−0.0%393% | 21+12.5%352% | 18−8.5%371% | 20+59.6%— | 12+26.3%— | 9.9−7.2%— | 11−9.3%— | 12r17−52.2%320% | 25−13.5%913% | 28—609% | |
| Operating income | −15—−293% | −15—−252% | −13—−271% | −20—— | −12—— | −9.6—— | −3.7—— | −8.8r−13—−239% | −21—−769% | −20—−423% | |
| Interest and finance income | 0.1−57.5%2.2% | 0.3−31.8%4.7% | 0.4+172%8.1% | 0.1+674%— | 0.0−62.0%— | 0.1−9.1%— | 0.1+27.9%— | 0.0+30.3%1.2% | 0.0+73.7%1.2% | 0.0—0.4% | |
| Interest expense and finance costs | 0.5+206%10.5% | 0.2−54.7%3.1% | 0.4−44.4%8.0% | 0.7−23.7%— | 0.9−15.8%— | 1.1−40.3%— | 1.9−3.5%— | 1.9−6.2%52.4% | 2.0−20.9%76.2% | 2.6—55.7% | |
| Other non-operating income (expense) | −7.1−513%−136% | 1.7+34240%29.5% | 0.0—0.1% | −0.6—— | −0.9−168%— | 1.3+259%— | 0.4—— | −0.1r0.1—−3.2% | −2.0—−74.5% | −2.3—−50.3% | |
| Income before tax | −22—−429% | −13—−223% | — | — | — | — | — | — | — | — | |
| Income tax | 0—0.0% | 0—0.0% | 0—0.0% | 0—— | 0—— | 0—— | 0—— | 0—0.0% | 0—0.0% | 0—0.0% | |
| Income from discontinued operations | — | — | — | — | — | 0—— | −7.6—— | −3.8—−102% | — | — | |
| Net income attributable to shareholders | −22—−429% | −13—−223% | −13—−271% | −20—— | −13—— | −8.2—— | −11—— | −13—−344% | −23—−844% | −22—−473% | |
| Earnings per share, basic | -0.29—— | -1.95—— | -4.24—— | -11.58r-0.77—— | -1.11—— | -1.86—— | -8.27—— | -86.98r-1.74—— | -8.23r-0.82—— | -1.28—— | |
| Earnings per share, diluted | -0.29—— | -2.34—— | -4.24—— | -11.58r-0.77—— | -1.11—— | -1.86—— | -8.27—— | -86.98r-1.74—— | -8.23r-0.82—— | -1.28—— | |
| Shares, weighted average (basic) | 78+1072%— | 6.6+111%— | 3.1+79.4%— | 1.8r26−85.5%— | 12—— | — | — | — | — | — | |
| Shares, weighted average (diluted) | 78+910%— | 7.7+145%— | 3.1+79.4%— | 1.8r26−85.5%— | 12+173%— | 4.4+220%— | 1.4+696%— | 0.2r8.7−94.6%— | 3.2r32−81.3%— | 17—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 4.3+5500%26.1% | 0.1−99.1%1.1% | 8.6−52.8%75.1% | 18−1.5%75.9% | 18+120%83.7% | 8.3−52.4%68.9% | 18+234%75.6% | 5.3−44.9%21.9% | 9.6−24.2%30.2% | 13r13—36.4% | |
| Short-term investments | 4.4+23.4%26.7% | 3.5—53.2% | — | — | — | — | — | — | — | — | |
| Receivables | — | — | — | — | — | 0−100%0.0% | 1.2+557%5.0% | 0.2r0.3+22.8%0.7% | 0.1−88.3%0.5% | 1.2—3.6% | |
| Inventory | — | — | — | — | — | — | 0.10.0%0.5% | 0.1r2.9−96.6%0.4% | 3.2−14.6%10.1% | 3.7—10.8% | |
| Other current assets | 1.7+60.3%10.6% | 1.1−15.5%16.3% | 1.3−65.4%11.2% | 3.7+179%15.5% | 1.3+59.7%6.0% | 0.8−13.4%6.8% | 1.0+21.9%4.1% | 0.8r1.1−40.1%3.3% | 1.3+50.7%4.1% | 0.9—2.5% | |
| Current assets | 15r15+182%91.0% | 5.3−46.5%79.3% | 9.8−54.9%86.4% | 22+10.6%91.4% | 20+115%89.7% | 9.2−53.7%75.8% | 20+105%85.3% | 9.6−35.1%40.2% | 15−20.7%47.0% | 19—54.2% | |
| Property, plant and equipment | 0.3−42.6%1.6% | 0.4−50.6%6.8% | 0.9−31.6%8.0% | 1.3−10.4%5.5% | 1.5−18.8%6.7% | 1.8−16.5%15.0% | 2.2−5.2%9.4% | 2.3r2.6−24.7%9.6% | 3.1+164%9.7% | 1.2—3.3% | |
| Right-of-use (leased) assets | 0.1−4.1%0.4% | 0.1−63.9%1.1% | 0.2−18.5%1.8% | 0.2−27.3%1.0% | 0.3−46.4%1.6% | 0.6−18.6%5.3% | 0.8—3.4% | — | — | — | |
| Goodwill | 0.40.0%2.3% | 0.40.0%5.6% | 0.40.0%3.3% | 0.40.0%1.6% | 0.40.0%1.7% | 0.40.0%3.1% | 0.40.0%1.6% | 0.4r3.9−90.5%1.6% | 3.90.0%12.4% | 3.9—11.3% | |
| Other intangible assets | 0.3−29.0%2.0% | 0.5+1017%7.1% | 0.0—0.4% | — | — | — | — | 6.0−17.3%24.8% | 7.2−14.7%22.8% | 8.4—24.4% | |
| Total assets | 16+146%100% | 6.6−41.8%100% | 11−52.3%100% | 24+8.6%100% | 22+81.6%100% | 12−47.9%100% | 23−3.2%100% | 24−24.1%100% | 32−8.7%100% | 35—100% | |
| Accounts payable | 3.3−65.4%20.1% | 9.5r9.5+99.1%143% | 4.8r4.8−43.1%41.8% | 8.4r8.4+220%35.0% | 2.6r2.6+231%11.9% | 0.8r0.8+141%6.5% | 0.3r0.3−54.6%1.4% | 0.7r0.7−44.4%3.0% | 1.3r1.3−2.6%4.1% | 1.3r1.3—3.8% | |
| Debt due within a year | — | — | 4.0+147%34.9% | 1.60.0%6.7% | 1.6−74.6%7.3% | 6.3−42.7%52.3% | 11−22.1%47.6% | 14+4.2%59.2% | 14+106%43.1% | 6.6—19.2% | |
| Current liabilities | 12−20.8%75.4% | 16+45.0%234% | 11−9.5%94.2% | 12+102%49.7% | 5.9−31.3%26.7% | 8.5−41.1%70.5% | 14−17.5%62.4% | 18−4.6%73.2% | 18+47.3%58.2% | 13—36.1% | |
| Long-term debt | — | — | — | 3.8−24.4%15.9% | 5.0—22.8% | — | — | — | 0−100%0.0% | 11—31.8% | |
| Lease liabilities (non-current) | 0.0−51.6%0.1% | 0.0−63.5%0.5% | 0.1−39.7%0.7% | 0.1−47.6%0.6% | 0.3−49.1%1.2% | 0.5−18.3%4.4% | 0.6—2.8% | — | — | — | |
| Total liabilities | 12−20.9%75.5% | 16+22.3%235% | 13−26.9%112% | 17+56.3%73.0% | 11+22.8%50.7% | 9.1−58.9%75.0% | 22+17.6%95.0% | 19+0.8%78.2% | 19−21.2%58.9% | 24—68.3% | |
| Retained earnings | −516—−3160% | −493—−7440% | −481—−4219% | −467—−1957% | −447—−2033% | −434—−3581% | −425—−1831% | −414—−1727% | −402—−1271% | −379—−1095% | |
| Shareholders' equity | 4.0—24.5% | −8.9—−135% | −1.3−121%−11.8% | 6.4−40.5%27.0% | 11+258%49.3% | 3.0+161%25.0% | 1.2−77.8%5.0% | 5.2−59.8%21.8% | 13+18.3%41.1% | 11—31.7% | |
| Total liabilities and equity | 16+146%100% | 6.6−41.8%100% | 11−52.3%100% | 24+8.6%100% | 22+81.6%100% | 12−47.9%100% | 23−3.2%100% | 24−24.1%100% | 32−8.7%100% | 35—100% | |
| Shares outstanding | 5.5r139−5.9%— | 5.9+32.7%— | 4.4r4.5+98.4%— | 2.2r34−85.6%— | 16+130%— | 6.7+73.9%— | 3.9+1208%— | 0.3r5.8−94.9%— | 5.8r58−73.4%— | 22—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 0.4−49.0%8.5% | 0.9r0.7+38.9%15.0% | 0.6+1.5%12.8% | 0.6+56.7%— | 0.4+7.9%— | 0.4−59.2%— | 0.9−55.3%— | 2.0−6.8%54.6% | 2.2+82.0%80.0% | 1.2—25.4% | |
| Share-based compensation | 1.5+180%29.5% | 0.6−3.3%9.4% | 0.6−6.1%11.6% | 0.60.0%— | 0.6+145%— | 0.2+94.5%— | 0.1−64.2%— | 0.4−52.9%9.7% | 0.8−30.3%28.0% | 1.1—23.2% | |
| Cash from operating activities | −21—−399% | −11—−181% | −13—−262% | −13—— | −10—— | −8.4—— | −5.9—— | −12—−326% | −18—−674% | −20—−420% | |
| Capital expenditure | −0.1—−1.3% | −0.1—−2.5% | −0.2—−3.3% | — | — | — | −0.1—— | −0.1—−3.6% | −0.3—−11.0% | −0.1—−1.4% | |
| Intangible assets bought | — | −0.5—−9.4% | — | — | 0—— | −0.4—— | 0—— | — | — | 0—0.0% | |
| Cash from investing activities | −0.9—−16.4% | −4.1—−70.6% | −0.2—−3.3% | −0.8—— | −0.1—— | −0.5−109%— | 5.6—— | −0.1—−3.6% | −1.4r−1.7−2261%−51.4% | 0.1—1.4% | |
| Debt issued | — | — | — | — | — | — | — | — | — | 0—0.0% | |
| Debt repaid | — | −4.0—−68.6% | −1.6—−32.7% | −1.6—— | −0.3—— | −5.3—— | −3.7—— | 0—0.0% | −4.7—−176% | 0—0.0% | |
| Shares issued | 23—434% | — | 5.5−65.1%112% | 16r15−15.2%— | 19+366%— | 4.0−74.9%— | 16—— | 0−100%0.0% | 24+10.0%878% | 21—461% | |
| Cash from financing activities | 30+390%581% | 6.2+79.6%106% | 3.4−74.4%70.1% | 13−34.1%— | 20—— | −0.3−103%— | 13+76.2%— | 7.2−57.4%195% | 17−4.5%625% | 18—378% | |
| Exchange-rate effect on cash | — | — | — | — | — | — | — | — | 0.0−86.6%0.4% | 0.1—1.8% | |
| Change in cash | 8.7—167% | −8.5—−146% | −9.6—−195% | −0.3−103%— | 10—— | −9.2−175%— | 12—— | −4.9—−134% | −2.7r−3.0—−99.9% | −1.8—−38.2% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 3.5−32.9%100% | 0.7−48.3%100% | 0.4−70.4%100% | 1.0−2.9%100% | 1.4*−3.2%100% | 1.4−4.1%100% | 1.4+8.7%100% | 1.1−36.9%100% | 1.4*—100% | 1.5—100% | 1.3—100% | 1.7—100% | — | |
| Research and development | 12+59.7%345% | 2.1−13.5%292% | 4.3+242%1038% | 2.9+63.2%279% | 2.9*+34.5%215% | 2.4−14.8%174% | 1.2−55.1%89.6% | 1.8−36.4%166% | 2.2*−21.8%155% | 2.9—196% | 2.8—217% | 2.8—165% | 2.8*—— | |
| Selling, general and administrative | — | 5.2+49.8%714% | — | — | — | 3.4—246% | — | — | — | — | — | — | — | |
| General and administrative | — | — | 5.2+209%1266% | 5.3+86.1%514% | 4.2*+33.3%305% | 3.4+43.6%246% | 1.7−23.6%121% | 2.8+28.3%268% | 3.1*+31.5%221% | 2.4—165% | 2.2—172% | 2.2—132% | 2.4r2.4*—— | |
| Operating expenses | 33+75.8%933% | 8.2+39.1%1133% | 9.5+223%2304% | 8.1+77.3%793% | 7.1*+33.8%520% | 5.9+11.9%421% | 2.9−41.2%211% | 4.6−7.7%434% | 5.3*+2.7%376% | 5.3—361% | 5.0—389% | 5.0—297% | 5.2r5.2*—— | |
| Operating income | −29—−833% | −7.5—−1033% | −9.1—−2204% | −7.1—−693% | −5.7*—−420% | −4.5—−321% | −1.5—−111% | −3.5—−334% | −3.9*—−276% | −3.8—−261% | −3.7—−289% | −3.3—−197% | −3.9r−3.9*—— | |
| Interest and finance income | 0.4+179%11.2% | 0.1+102%16.5% | 0.1+107%13.6% | 0.2+18900%18.5% | 0.0*−46.3%2.1% | 0.1−26.2%4.2% | 0.0−59.7%1.9% | 0.0−98.6%0.1% | 0.1*−50.9%3.8% | 0.1—5.5% | 0.1—5.2% | 0.1—4.3% | 0.1*—— | |
| Interest expense and finance costs | 0.0−94.0%1.0% | 0.0—1.9% | 0.0—1.2% | 0.0−96.9%1.7% | 0*−100%0.0% | 0*−100%0.0% | 0*−100%0.0% | 0.5+1512%51.7% | 0.1*−8.1%4.0% | 0.1—4.2% | 0.0—2.1% | 0.0—2.0% | 0.1*—— | |
| Other non-operating income (expense) | −0.9—−26.9% | −1.2−2137%−166% | 0.1−99.2%12.4% | 0.2—16.8% | 0.0*—2.1% | 0.1−93.6%4.2% | 6.7+784%481% | −14−36587%−1309% | −0.0*−106%−0.2% | 0.9—63.5% | 0.8—59.2% | 0.0—2.3% | 0.0r0.1*—— | |
| Net income attributable to shareholders | −30—−859% | −8.7—−1199% | −9.0−275%−2191% | −6.9—−676% | −5.7*—−418% | −4.4—−317% | 5.2—371% | −17—−1643% | −3.9*—−276% | −2.9—−197% | −2.9—−230% | −3.3—−194% | −3.8*—— | |
| Earnings per share, basic | — | -1.14—— | -1.31−311%— | -1.05—— | — | -1.03r-0.04—— | 0.62r0.02—— | -29.86r-1.19—— | — | -0.37—— | -0.45—— | -0.75—— | — | |
| Earnings per share, diluted | — | -1.14—— | -1.31—— | -1.05—— | — | -1.03r-0.04—— | -0.16r-0.01—— | -29.86r-1.19—— | — | -0.37—— | -0.71—— | -0.75—— | — | |
| Shares, weighted average (basic) | 7.6+76.1%— | 7.6+76.1%— | 6.9+256%— | 6.6+1041%— | — | 4.3r107−45.3%— | 1.9r48−70.2%— | 0.6r15−86.5%— | — | 7.9—— | 6.5—— | 4.3—— | — | |
| Shares, weighted average (diluted) | 7.6+76.1%— | 7.6+76.1%— | 6.9−17.5%— | 6.6+1041%— | — | 4.3r107−45.3%— | 8.4r209−22.1%— | 0.6r15−86.5%— | — | 7.9—— | 11—— | 4.3—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 0.9—7.2% | 0.9−93.4%7.2% | 2.4+6.0%16.9% | 3.0−69.4%15.2% | 4.3+5500%26.1% | 13+987%71.2% | 2.2−54.5%21.6% | 9.9+240%81.8% | 0.1−99.1%1.1% | 1.2—17.5% | 4.9—43.8% | 2.9—51.6% | 8.6—75.1% | |
| Short-term investments | 4.0—32.7% | 4.0+20.5%32.7% | 6.2+33.9%44.3% | 12—60.7% | 4.4+23.4%26.7% | 3.3−7.1%17.7% | 4.6+31.9%44.9% | — | 3.5—53.2% | 3.6—51.1% | 3.5—31.4% | 0.3—5.7% | — | |
| Receivables | 0.7—5.9% | 0.7—5.9% | — | — | — | — | — | — | — | — | — | — | — | |
| Inventory | 0.2—1.9% | 0.2—1.9% | — | — | — | — | — | — | — | — | — | — | — | |
| Other current assets | 2.2—18.4% | 2.2+127%18.4% | 1.4+8.3%10.1% | 1.6+56.2%7.9% | 1.7+60.3%10.6% | 1.0+71.0%5.3% | 1.3+39.0%12.7% | 1.0+1.2%8.3% | 1.1−15.5%16.3% | 0.6—8.3% | 0.9—8.4% | 1.0—17.6% | 1.3—11.2% | |
| Current assets | 8.1—66.1% | 8.1−54.1%66.1% | 12+27.8%83.9% | 18+65.9%90.5% | 15r15+182%91.0% | 18+228%94.2% | 9.2−1.8%89.0% | 11+158%90.1% | 5.3−46.5%79.3% | 5.4—76.9% | 9.4—83.7% | 4.2—75.0% | 9.8—86.4% | |
| Property, plant and equipment | 1.3—11.1% | 1.3+394%11.1% | 1.4+388%10.0% | 1.0+213%5.1% | 0.3−42.6%1.6% | 0.3−53.8%1.5% | 0.3−60.5%2.8% | 0.3−59.5%2.7% | 0.4−50.6%6.8% | 0.6—8.5% | 0.7—6.5% | 0.8—14.2% | 0.9—8.0% | |
| Right-of-use (leased) assets | 0.0—0.2% | 0.0+45.0%0.2% | 0.0+48.3%0.3% | 0.1+50.0%0.3% | 0.1−4.1%0.4% | 0.0−81.1%0.1% | 0.0−79.1%0.3% | 0.0−77.8%0.3% | 0.1−63.9%1.1% | 0.1—1.5% | 0.1—1.2% | 0.2—3.0% | 0.2—1.8% | |
| Goodwill | 0.4—3.0% | 0.40.0%3.0% | 0.40.0%2.7% | 0.40.0%1.9% | 0.40.0%2.3% | 0.40.0%2.0% | 0.40.0%3.6% | 0.40.0%3.1% | 0.40.0%5.6% | 0.4—5.3% | 0.4—3.3% | 0.4—6.6% | 0.4—3.3% | |
| Other intangible assets | — | — | — | — | 0.3−29.0%2.0% | — | — | — | 0.5+1017%7.1% | — | — | — | 0.0—0.4% | |
| Total assets | 12—100% | 12−34.7%100% | 14+35.6%100% | 20+65.2%100% | 16+146%100% | 19+168%100% | 10−7.7%100% | 12+114%100% | 6.6−41.8%100% | 7.0—100% | 11—100% | 5.6—100% | 11—100% | |
| Accounts payable | 8.2—67.3% | 8.2−29.4%67.3% | 7.6+18.7%53.8% | 6.2−33.2%30.9% | 3.3−65.4%20.1% | 12+46.9%62.3% | 6.4−8.5%61.4% | 9.2+43.0%76.5% | 9.5r9.5+99.1%143% | 7.9—113% | 6.9—62.0% | 6.4—115% | 4.8r4.8—41.8% | |
| Debt due within a year | — | — | — | — | — | — | — | — | — | — | — | 3.6—63.9% | 4.0—34.9% | |
| Current liabilities | 13—108% | 13−3.6%108% | 8.6+17.1%61.1% | 8.0−24.7%39.9% | 12−20.8%75.4% | 14+12.4%72.9% | 7.3−61.1%70.7% | 11+1.5%87.6% | 16+45.0%234% | 12—174% | 19—168% | 10—185% | 11—94.2% | |
| Lease liabilities (non-current) | — | — | — | — | 0.0−51.6%0.1% | — | — | — | 0.0−63.5%0.5% | 0.0—0.6% | 0.1—0.4% | 0.1—1.0% | 0.1—0.7% | |
| Total liabilities | 13—108% | 13−3.6%108% | 8.6+17.1%61.1% | 8.0−77.7%39.9% | 12−20.9%75.5% | 14+12.0%72.9% | 7.3−61.2%70.7% | 36+241%296% | 16+22.3%235% | 12—174% | 19—168% | 10—186% | 13—112% | |
| Retained earnings | −540—−4430% | −540—−4430% | −532—−3791% | −523—−2625% | −516—−3160% | −510—−2732% | −506—−4886% | −511—−4238% | −493—−7440% | −490—−7016% | −487—−4341% | −484—−8606% | −481—−4219% | |
| Shareholders' equity | −0.9—−7.6% | −0.9−118%−7.6% | 5.5+80.1%38.9% | 12—60.1% | 4.0—24.5% | 5.1—27.1% | 3.0—29.3% | −24—−196% | −8.9—−135% | −5.2—−74.1% | −7.6—−68.0% | −4.8—−86.1% | −1.3—−11.8% | |
| Total liabilities and equity | 12—100% | 12−34.7%100% | 14+35.6%100% | 20+65.2%100% | 16+146%100% | 19+168%100% | 10−7.7%100% | 12+114%100% | 6.6−41.8%100% | 7.0—100% | 11—100% | 5.6—100% | 11—100% | |
| Shares outstanding | 7.9—— | 7.9−94.0%— | 7.3−92.1%— | 6.9−59.6%— | 5.5r139−5.9%— | 132+2132%— | 92+1516%— | 17+299%— | 5.9+32.7%— | 5.9—— | 5.7—— | 4.3—— | 4.4r4.5—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.5−19.3%14.8% | 0.1*+88.3%20.1% | 0.1*+77.9%33.3% | 0.1−34.2%9.3% | 0.1*−58.3%10.6% | 0.1*−61.3%5.5% | 0.1*−54.7%5.5% | 0.1−5.8%13.8% | 0.3r0.2*+130%24.6% | 0.2*—13.7% | 0.2*—13.3% | 0.2—9.2% | 0.2*—— | |
| Share-based compensation | 3.3+243%92.8% | 0.7*+34.5%98.2% | 0.8*+446%202% | 1.0+591%99.4% | 0.7*+457%52.2% | 0.5*+322%37.7% | 0.2*+0.7%10.9% | 0.1+1.4%14.0% | 0.1*−9.2%9.1% | 0.1*—8.6% | 0.2*—11.8% | 0.1—8.7% | 0.1*—— | |
| Cash from operating activities | −27—−774% | −7.7*—−1063% | −7.1*—−1735% | −6.2—−607% | −6.3*—−458% | −2.5*—−182% | −5.8*—−417% | −6.2—−583% | −1.2*—−85.8% | −3.7*—−253% | −1.2*—−89.9% | −4.5—−269% | −1.9*—— | |
| Capital expenditure | −1.4—−39.6% | −0.1*—−7.1% | −0.5*—−121% | −0.8—−79.6% | −0.0*—−2.2% | −0.0*—−1.9% | −0.0*—−0.5% | −0.0—−0.3% | −0.0*—−0.8% | −0.0*—−1.0% | −0.1*—−6.3% | −0.0—−2.4% | −0.0*—— | |
| Intangible assets bought | — | — | — | — | — | — | — | — | 0*—0.0% | 0*—0.0% | — | — | — | |
| Cash from investing activities | −2.2−881%−63.5% | 2.0*+54.4%277% | 5.4*—1306% | −8.5−340%−830% | −1.1*−1783%−78.8% | 1.3*—92.8% | −4.6*—−333% | 3.6—336% | 0.1*—4.5% | −0.0*—−0.6% | −3.8*—−297% | −0.4—−21.7% | −0.0*—— | |
| Debt repaid | — | — | — | — | — | — | — | — | 0*—0.0% | 0*—0.0% | −3.6*—−281% | −0.4—−24.0% | −0.4*—— | |
| Shares issued | — | — | — | — | 3.0*—220% | 17*—1204% | — | — | — | — | — | — | 0.3*—— | |
| Cash from financing activities | 17−37.7%486% | 4.2*−66.0%580% | 1.1*−60.3%270% | 9.0−27.2%879% | 2.8*—205% | 12*—881% | 2.8*−59.8%201% | 12—1171% | 0*—0.0% | 0*—0.0% | 7.0*—544% | −0.8—−46.3% | −0.5*—— | |
| Change in cash | −12−203%−352% | −1.5*−113%−206% | −0.7*—−160% | −5.7−159%−558% | −4.5*—−331% | 11*—791% | −7.6*−480%−549% | 9.8—925% | −1.1*—−81.2% | −3.7*—−253% | 2.0*—157% | −5.7—−337% | −2.5*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Executive pay at Cerenome, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Marc H. Hedrick, M.D | $5.6 M | $4.7 M | $1.6 M | $11 |
| 2024Marc H. Hedrick, M.D | $1.3 M | $1.6 M | $907 K | $24 |
| 2023Marc H. Hedrick, M.D | $1.1 M | $1.6 M | $1.2 M | $37 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Cerenome, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Auditor changedFiling
Auditor changed 1 · Directors and officers 4 · Material agreement 5 · New debt 2 · Unregistered share sale 2 · Shareholder rights changed 1 · Bylaws or fiscal year changed 2 · Shareholder vote 2 · Results announced 5
| Filed | What happened | Filing |
|---|---|---|
| Directors and officers | 8-K | |
| Material agreementNew debtUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Material agreementNew debt | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Auditor changed | 8-K | |
| Material agreementUnregistered share sale | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2019 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Cerenome, Inc. compares in Biotechnology
- Market cap$17 M · higher than 16% of 726
- Revenue$5 M · higher than 36% of 647
- Net margin-621.4% · higher than 8% of 408
- Revenue growth-10.5% · higher than 34% of 438
- Price / sales4.0× · lower than 67% of 339
- Price / book4.3× · lower than 36% of 534
- FCF yield-122.6% · higher than 8% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Cerenome, Inc.🇺🇸 | $17 M | — | -621.4% | -10.5% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, Wikidata; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Cerenome, Inc.? Verify and update this profile — free
Show Cerenome, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.